The global autoimmune disease diagnostics market Size is anticipated to reach over USD 5,054.12 Million by 2026, according to a new research published by Polaris Market Research
In general, our body immune system protects the body from foreign particles such as virus and bacteria. Autoimmune diseases arise when the body immune system attacks one or more healthy cells which are operating normally the cause for this may be the irregularities of genes. The malfunctioning of a body immune system is the outcome of the failure to identify organs, tissues, immune cells, and generating autoantibodies targeting these cells.
Autoimmune disease diagnostics market is predominantly driven by key factors such as the increasing occurrence of autoimmune disease. for instance, according to The National Institutes of Health (NIH) 2015, approximately 23.5 million Americans were affected by autoimmune disease. Moreover, increase in automation technologies, patient consciousness regarding rising healthcare concerns, increasing government support, increase in healthcare spending, and easy and rapid performing diagnosis test results and prevention of disease are another factors boosting the market growth. However, huge turnaround time for diagnostic test results, high cost associated with the diagnostics tests, and high frequency of false-positive results are some of the major factors hindering the global autoimmune diagnostics market growth. In addition, lack of awareness concerning the various diseases and diagnostic procedures are another factors affecting the market growth adversely.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:
The global autoimmune disease diagnostics market is segmented on the basis of type, end user, and geography. On the basis of type, the global autoimmune disease diagnostics market is segmented into systemic autoimmune disease diagnostics and localized autoimmune disease diagnostics. The systemic autoimmune disease diagnostics is further categorized into rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), and others. On the other side, the localized autoimmune disease diagnostics is further categorized into multiple sclerosis, type 1 diabetes, hashimoto’s thyroiditis, idiopathic thrombocytopenic purpura, and others. In 2017, localized disease diagnostics dominated the overall market. The dominance is majorly attributed to the existence of large process measurements and moderately higher patient awareness level in comparison to systemic diseases. On the basis of end users, the global autoimmune disease diagnostics market is segmented into Hospitals, Diagnostics Centers, and Research Laboratories.
In terms of geography, North America is estimated to dominate the global autoimmune disease diagnostics market. The dominance is majorly attributed to increasing prevalence of some of the common autoimmune diseases such as type1 diabetes and rheumatoid arthritis. The surge in funding by private and government organizations, growing regulatory scenario observed by World Health Organization (WHO), and advancement in technology are some of the other factors driving the growth of the autoimmune disease diagnostics market in North America.
Some major key players in global autoimmune disease diagnostics market includes Haemonetics Corporation, Fresenius Kabi (Fenwal), Asahi Kasei Kuraray Medical Co. Ltd., Terumo BCT, Inc., HemaCare Corporation, Therakos, Inc. and B. Braun Melsungen AG among others.